Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Study With Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naive Subjects With Chronic Hepatitis C Genotype 1b Infection
Brief Summary: The purpose of this study is to estimate efficacy, as determined by the proportion of subjects with Sustained virologic response at post-treatment Week 12 (SVR12), defined as Hepatitis C virus (HCV) Ribonucleic acid (RNA) \< Limit of quantitation (LOQ) at post-treatment Week 12, for subjects who are prior null or partial responders to P/R or who are treatment-naive.


Options:
A: Arm Label: Arm 1: Null or Partial Responder to P/R (ASV + DCV); Type: EXPERIMENTAL; Interventions: Drug: Asunaprevir (ASV), Drug: Daclatasvir (DCV) | Arm Label: Arm 2: Intolerant to or Ineligible for P/R (ASV + DCV); Type: EXPERIMENTAL; Interventions: Drug: Asunaprevir (ASV), Drug: Daclatasvir (DCV) | Arm Label: Arm 3: Treatment naive (ASV + DCV); Type: EXPERIMENTAL; Interventions: Drug: Asunaprevir (ASV), Drug: Daclatasvir (DCV), Drug: Pegylated-interferon alfa 2a (PegIFN), Drug: Ribavirin (RBV) | Arm Label: Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week; Type: EXPERIMENTAL; Interventions: Drug: Asunaprevir (ASV), Drug: Daclatasvir (DCV), Drug: Pegylated-interferon alfa 2a (PegIFN), Drug: Ribavirin (RBV) | Intervention Type: DRUG; Name: Asunaprevir (ASV); Assigned to Arm(s): Arm 1: Null or Partial Responder to P/R (ASV + DCV), Arm 2: Intolerant to or Ineligible for P/R (ASV + DCV), Arm 3: Treatment naive (ASV + DCV), Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week | Intervention Type: DRUG; Name: Daclatasvir (DCV); Assigned to Arm(s): Arm 1: Null or Partial Responder to P/R (ASV + DCV), Arm 2: Intolerant to or Ineligible for P/R (ASV + DCV), Arm 3: Treatment naive (ASV + DCV), Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week | Intervention Type: DRUG; Name: Pegylated-interferon alfa 2a (PegIFN); Assigned to Arm(s): Arm 3: Treatment naive (ASV + DCV), Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): Arm 3: Treatment naive (ASV + DCV), Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: danoprevir, Drug: peginterferon alfa-2a [Pegasys], Drug: ribavirin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: danoprevir, Drug: peginterferon alfa-2a [Pegasys], Drug: ribavirin, Drug: ritonavir | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: peginterferon alfa-2a [Pegasys], Drug: placebo, Drug: ribavirin, Drug: ritonavir | Intervention Type: DRUG; Name: danoprevir; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: peginterferon alfa-2a [Pegasys]; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C | Intervention Type: DRUG; Name: ribavirin; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: ritonavir; Assigned to Arm(s): B, C
C: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: BI 201335, Drug: BI 207127 | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: BI 201335, Drug: Ribavirin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: BI 201335, Drug: Ribavirin | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: Ribavirin, Drug: BI 201335 | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: BI 201335, Drug: BI 207127, Drug: Ribavirin | Arm Label: 6; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: BI 201335, Drug: BI 207217 | Arm Label: 7; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: BI 201335 | Arm Label: 8; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: Ribavirin, Drug: BI 201335 | Arm Label: 9; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: BI 201335, Drug: Ribavirin | Arm Label: 10; Type: EXPERIMENTAL; Interventions: Drug: BI 201335, Drug: BI 207127, Drug: Ribavirin | Arm Label: 11; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: BI 207127, Drug: BI 201335 | Arm Label: 12; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: BI 201335, Drug: BI 207127 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 11 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 9 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 11 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 10 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 7 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 11 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 12 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 12 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 7 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 12 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 9 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 8 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 8 | Intervention Type: DRUG; Name: BI 207217; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 8 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 10 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 9 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 10
D: Arm Label: SOF+PEG+RBV 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV, Drug: PEG | Arm Label: SOF+PEG+RBV 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV, Drug: PEG | Arm Label: SOF+PEG+RBV 12 week/Rerandomization Group; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV, Drug: PEG | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): SOF+PEG+RBV 12 week/Rerandomization Group, SOF+PEG+RBV 12 weeks, SOF+PEG+RBV 24 weeks | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): SOF+PEG+RBV 12 week/Rerandomization Group, SOF+PEG+RBV 12 weeks, SOF+PEG+RBV 24 weeks | Intervention Type: DRUG; Name: PEG; Assigned to Arm(s): SOF+PEG+RBV 12 week/Rerandomization Group, SOF+PEG+RBV 12 weeks, SOF+PEG+RBV 24 weeks

Answer: A